
|Videos|September 12, 2014
Adjuvant Capecitabine/Gemcitabine for EHCC and GBCA
Author(s)Melanie B. Thomas, MD
Melanie B. Thomas, MD, discusses the rationale of a phase II study of adjuvant capecitabine/gemcitabine for extrahepatic cholangiocarcinoma and gallbladder carcinoma.
Advertisement
Clinical Pearls
Melanie B. Thomas, MD, medical oncologist, associate director for clinical trials, Hollings Cancer Center, Medical University of South Carolina, discusses the rationale of a phase II study of adjuvant capecitabine/gemcitabine for extrahepatic cholangiocarcinoma and gallbladder carcinoma.
- Though surgery is the only curative option for patients with extrahepatic cholangiocarcinoma (EHCC) and gallbladder carcinomas (GBCA), there is still a high risk of the cancer returning.
- There remains a need for an option for these patients after surgery.
- This trial established the feasibility of adjuvant treatment in EHCC and GBCA.
More on this study > >
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Giredestrant/Everolimus Improves PFS Across Subgroups After CDK4/6i in ER+/HER2– Breast Cancer
5









































